Newsletter - Synexus News Edition 3

Inside This Issue

Chief Executive of Synexus in the UK final of the Ernst & Young Entrepreneur of the Year Awards 2010

Reaching out to patients

Investment in Doppler ultrasound vital to diabetes studies

MHRA in full support of clinical trials in the UK

Overseas; a bigger issue than any of us realised?

Social Media Marketing: the future or just a fad?

Further expansion into Poland

Useful Links

Industry Focus

Reaching out to patients

Mild cognitive impairment is a growing area of interest for clinical studies. Yet, how easy it is to find patients who are unlikely to present to their healthcare practitioner?
read more »

Synexus News

Chief Executive of Synexus in the UK final of the Ernst & Young Entrepreneur of the Year Awards 2010

Michael Fort, Chief Executive of Synexus has gone through to the UK final of the Ernst & Young Entrepreneur of the Year Awards 2010 after being named North West and Midlands Turnaround Entrepreneur in this year’s competition.

Michael Fort’s tenacity and entrepreneurial spirit has allowed the business to gather momentum and grow at an exponential rate and it was recognition of this which enabled Michael to gain this prestigious award.

Investment in Doppler ultrasound vital to diabetes studies

A recent investment in Doppler ultrasound equipment will enable Synexus to be able to confirm a diagnosis of Peripheral Artery Disease (PAD) in patients with type 2 diabetes. As this equipment is not widely available at GP Practices patients are referred to a specialist consultant for a PAD test; often involving a wait of several weeks. This significant investment will support Synexus’ objective of ensuring clinical trials remain in the UK.

Michael Fort, Synexus’ Chief Executive is confident that continued investment in diagnostic equipment is vital to delivering clinical trials on time in the UK: “We need to take action that makes joining a clinical trial more attractive to patients and we need to show GPs that we really can make a difference to their patients by delivering faster diagnoses and first class medical care whilst their patients are part of our studies. At Synexus we continue to buck the trend against clinical trials recruitment in the UK. Since 2005 we have increased patients taking part in clinical trials here from one thousand to more than five thousand in 2009 and will continue to work to increase these numbers.”

Social Media Marketing: the future or just a fad?

It is difficult to find a brand nowadays which doesn’t ask consumers to ‘Follow us on Twitter’ or ‘Join us on Facebook’. Does the Social Media Marketing (SMM) phenomenon have a place in clinical trials or it is best avoided?
read more »

Further expansion into Poland

With a population of over 300 million Central and Eastern Europe offers a number of opportunities for clinical trials. Synexus already has a firm foot-hold in this region with Dedicated Research Centres in Poland, Hungary, Bulgaria and the Ukraine. It is also continuing to expand its capacity and resources in Poland with a new Dedicated Research Centre in Gdynia which will be fully operational by the end of the year.
read more »

Networking Update

MHRA in full support of clinical trials in the UK

At a recent Chairman’s Dinner Synexus discussed the importance of keeping clinical trials in the UK with MHRA Chief Executive Professor Kent Woods.
read more »

Industry Comment

Overseas; a bigger issue than any of us realised?

The number of new drugs whose human trials took place in foreign climes has been of considerable concern to medical ethicists for years. A report from the Health and Human Services Inspector General suggests that their fears were indeed founded as the scale of the issue is considerably greater than first thought.
read more »

Created with Newsweaver